Compare PepsiCo, Inc. (PEP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs TransMedics Group Inc — how do they compare? PepsiCo, Inc. trades at $135.8 (market cap $184.26B), while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: PepsiCo, Inc. is far larger — about 71.7× TransMedics Group Inc's market cap, and PepsiCo, Inc. pays a 4.39% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PEP | TMDX | |
|---|---|---|
Market Cap | $184.26B | $2.57B |
Sector | Consumer Staples | Technology |
52-Week High | $170.44 | $150.42 |
52-Week Low | $134.98 | $61.99 |
Enterprise Value | $226.76B | $2.97B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, showing minimal daily movement with a slight 0.14% gain. The technical outlook is bearish per moving averages, while fundamentals reflect steady revenue near $94B and strong profitability with a 10.78% net margin. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, alongside ongoing North American recovery efforts ahead of Q1 2026 earnings.
The stock presents a mixed outlook: analyst consensus leans hold (64% of ratings) with a $158.79 price target suggesting upside, but risks include margin pressure from pricing strategies and volatile cash flows. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings, indicating cautious optimism amid competitive and consumer sentiment challenges.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
